Celgene Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the market, how pro-patients and pro-innovation policies need to be supported, how innovative ways need to be found to ensure patient…
R&D Fermin Rivas Lopez, Country Manager of Celgene Portugal, gives his insight on Portugal’s recent economic problems, the challenges Celgene Portugal faces due to the economic state of the country, and what the strategy is to stay afloat. You joined Celgene Portugal earlier this year; why were you chosen to take…
Biopharmaceutical Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty pharma using Canada’s strong clinical base. What do Canadian biopharmaceutical companies offer as a competitive edge? I believe we have…
Celgene China Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially joined Celgene on January 1st, 2011. Before that, I worked for Abraxis BioScience, a US-based biopharmaceutical company, which entered China…
Celgene Australia In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that the number of listings has decreased to a point where Australia is in danger of losing its attractiveness as an…
Celgene Australia “Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008. Since then, what have been the highlights in the Celgene development in this part of the world? When Celgene decided…
Celgene UK and Ireland Celgene just announced very impressive second quarter results for its global operations, with a 38% increase in revenue partly led by strong growth in Europe. Within the global performance of the company, how would you assess the performance of the UK in 2010/2011? This year has been somewhat of a…
Celgene Hungary The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies to be adjusting their strategies in this market? The government has a large majority in the parliament since 2 years,…
Celgene As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of predominantly innovative medicines in haematology and oncology, it makes sense that the government looks to cut costs in the generic…
Celgene Russia Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and internal reasons, which coincided in this case. The external reason was the launch of the reimbursement system in Russia, which…
Celgene Taiwan Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene is very new entrant in the multinational context as a latecomer to the market. As a biopharmaceutical company it is…
Celgene France In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head of Celgene France’s operations, what were the main milestones of the company since its establishment in the French market in…
See our Cookie Privacy Policy Here
